Novo Nordisk A/S
APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF

Abstract:

The present invention relates to an antiarrhythmic agent for use in a method for the treatment of heart failure by transplantation of stem cell-derived cardiomyocytes, an antiarrhythmic cardiomyocyte cell population, a method for obtaining the antiarrhythmic cardiomyocyte cell population by in vitro exposure of stem cell derived cardiomyocytes to antiarrhythmic agent, and/or medical use of the antiarrhythmic cardiomyocyte cell population in the prevention of arrhythmia and treatment of heart failure. Specifically, the present invention relates to the transplantation of an antiarrhythmic cardiomyocyte cell population or co-administration of antiarrhythmic agent in vivo with transplanted stem cell derived cardiomyocytes.